Success Metrics

Clinical Success Rate

100.0%

Based on 10 completed trials

Completion Rate

100%(10/10)

Active Trials

1(6%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_4

28%

Ph phase_1

Ph phase_2

22%

Ph phase_3

28%

Ph early_phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution17 total trials

Early Phase 1First-in-human

2(11.8%)

Phase 1Safety & dosage

1(5.9%)

Phase 2Efficacy & side effects

4(23.5%)

Phase 3Large-scale testing

5(29.4%)

Phase 4Post-market surveillance

5(29.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(10)

Other(7)

Detailed Status

Completed10

unknown7

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (11.8%)

Phase 11 (5.9%)

Phase 24 (23.5%)

Phase 35 (29.4%)

Phase 45 (29.4%)

Trials by Status

recruiting16%

unknown739%

completed1056%

Recent Activity

1 active trials

Showing 5 of 18

completedphase_4

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

NCT05303584

completedphase_2

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

NCT05230940

completedphase_3

Clinical Trials (18)

Showing 18 of 18 trials

NCT05303584Phase 4

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

Completed

NCT05230940Phase 2

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

Completed

NCT04582344Phase 3

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)

Completed

NCT04754698Phase 4

COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS

Completed

NCT05897190Phase 1

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

Completed

NCT04942405Phase 3

Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine

Completed

NCT05077176Phase 3

Phase 3 Booster Vaccination Against COVID-19

Completed

NCT05593042Phase 2

Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile

Completed

NCT04800133Phase 2

Covid-19 Vaccination in Adolescents and Children

Unknown

NCT05057169Phase 4

Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)

Unknown

NCT04979949Phase 2

Booster Vaccination Against COVID-19

Completed

NCT04775069Phase 4

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

Completed

NCT05928455Early Phase 1

The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

Unknown

NCT05428592Phase 3

Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad

Unknown

NCT05683561Phase 3

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

Unknown

NCT05583357Early Phase 1

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

Unknown

NCT04834869

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting

NCT04801667Phase 4

Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients

Unknown

All 18 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 18